MX347320B - Anticuerpo bloqueador de agr2 y uso del mismo. - Google Patents

Anticuerpo bloqueador de agr2 y uso del mismo.

Info

Publication number
MX347320B
MX347320B MX2014000260A MX2014000260A MX347320B MX 347320 B MX347320 B MX 347320B MX 2014000260 A MX2014000260 A MX 2014000260A MX 2014000260 A MX2014000260 A MX 2014000260A MX 347320 B MX347320 B MX 347320B
Authority
MX
Mexico
Prior art keywords
agr2
blocking antibody
antibody
blocking
disclosed
Prior art date
Application number
MX2014000260A
Other languages
English (en)
Other versions
MX2014000260A (es
Inventor
Li Dawei
Wu Zhenghua
Guo Hao
Zhu Qi
S Mashausi Dhahiri
Original Assignee
Univ Shanghai Jiaotong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Shanghai Jiaotong filed Critical Univ Shanghai Jiaotong
Publication of MX2014000260A publication Critical patent/MX2014000260A/es
Publication of MX347320B publication Critical patent/MX347320B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un anticuerpo monoclonal bloqueador de AGR2, y en particular, un anticuerpo monoclonal humanizado para bloquear AGR2. También se describe una composición farmacéutica que contiene el anticuerpo y un método para preparar el mismo, y un uso del anticuerpo en el bloqueo del crecimiento tumoral y de la metástasis.
MX2014000260A 2011-07-05 2012-07-05 Anticuerpo bloqueador de agr2 y uso del mismo. MX347320B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2011101864695A CN102268089A (zh) 2011-07-05 2011-07-05 Agr2阻断抗体及其用途
PCT/CN2012/000926 WO2013004076A1 (zh) 2011-07-05 2012-07-05 Agr2阻断抗体及其用途

Publications (2)

Publication Number Publication Date
MX2014000260A MX2014000260A (es) 2014-09-01
MX347320B true MX347320B (es) 2017-04-21

Family

ID=45050566

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014000260A MX347320B (es) 2011-07-05 2012-07-05 Anticuerpo bloqueador de agr2 y uso del mismo.

Country Status (13)

Country Link
US (2) US9574012B2 (es)
EP (1) EP2749573B1 (es)
JP (1) JP6127043B2 (es)
KR (1) KR20140093922A (es)
CN (2) CN102268089A (es)
AU (1) AU2012278751B2 (es)
BR (1) BR112014000181A2 (es)
CA (1) CA2841372A1 (es)
MX (1) MX347320B (es)
RU (1) RU2610665C2 (es)
SG (1) SG10201605435TA (es)
TW (1) TWI588154B (es)
WO (1) WO2013004076A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102268089A (zh) * 2011-07-05 2011-12-07 上海交通大学 Agr2阻断抗体及其用途
KR101588285B1 (ko) * 2013-06-04 2016-01-25 한국생명공학연구원 소포체 스트레스로 인한 세포사멸을 약화시키는 agr2 호모-다이머
US8999007B2 (en) * 2013-07-12 2015-04-07 Ostara Nutrient Recovery Technologies Inc. Method for fines control
US9790488B2 (en) 2013-08-02 2017-10-17 Agency For Science, Technology And Research Mutated internal ribosomal entry site (IRES) for controlled gene expression
JP2017534251A (ja) * 2014-09-09 2017-11-24 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Ａｇｒ２およびその受容体ｃ４．４ａに対する遮断モノクローナル抗体
CN104593333B (zh) * 2014-12-12 2017-07-21 上海交通大学 稳定表达抗agr2人源化单克隆抗体的cho细胞株及其应用
KR101634612B1 (ko) * 2015-12-29 2016-06-29 한국생명공학연구원 소포체 스트레스로 인한 세포사멸을 약화시키는 agr2 호모-다이머
WO2017156280A1 (en) * 2016-03-09 2017-09-14 Viba Therapeutics, Inc. Methods of treating cancer using monoclonal antibodies to agr2 and c4.4a
CN106632680A (zh) * 2016-12-27 2017-05-10 上海交通大学 植物体系表达人源化抗agr2单克隆抗体18a4的质粒构建
MX2021002333A (es) 2018-08-30 2021-04-28 Univ Montreal Metodo basado en proteogenomica para identificar antigenos especificos de tumores.
JP7592585B2 (ja) * 2018-10-04 2024-12-02 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 粘膜炎症性疾患の処置のための方法及び医薬組成物
CN109576229A (zh) * 2018-12-13 2019-04-05 华中科技大学同济医学院附属协和医院 一种分泌抗agr2的单克隆抗体杂交瘤细胞株及其应用
CN113336853B (zh) * 2020-11-04 2022-06-14 华中科技大学同济医学院附属协和医院 针对agr3蛋白的单克隆抗体、制备方法及其应用
EP4274617A4 (en) * 2021-01-05 2025-04-02 Musc Foundation for Research Development A BISPECIFIC AGR2XCD3 ENGAGER FOR THE TREATMENT OF CANCER
CN120530137A (zh) * 2022-11-21 2025-08-22 泰博尔治疗公司 人源化抗agr2抗体
WO2025109043A2 (en) 2023-11-22 2025-05-30 Institut National de la Santé et de la Recherche Médicale Use of neutralizing anti-agr2 antibodies for preventing resistance to chemotherapy
WO2025242685A1 (en) * 2024-05-20 2025-11-27 Thabor Therapeutics Optimized anti-agr2 antibody
WO2025242680A1 (en) * 2024-05-20 2025-11-27 Thabor Therapeutics Humanized anti-agr2 antibody
CN119959532B (zh) * 2025-01-03 2025-11-11 中国科学院精密测量科学与技术创新研究院 细胞色素c在制备elisa试剂盒方面的新用途
CN121796603B (zh) * 2026-03-06 2026-07-28 浙江大学 一种靶向pdia3蛋白的单克隆抗体及其在治疗乳腺癌中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
US7229960B2 (en) * 2000-11-03 2007-06-12 University Of Vermont And State Agricultural College Methods and compositions for inhibiting GRB7
GB0222787D0 (en) * 2002-10-02 2002-11-06 Univ Liverpool Metastasis inducing compounds
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
KR20140053410A (ko) * 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
GB0611116D0 (en) * 2006-06-06 2006-07-19 Oxford Genome Sciences Uk Ltd Proteins
GB0616929D0 (en) * 2006-08-26 2006-10-04 Univ Liverpool Antibodies, assays and hybridomas
MX2011000655A (es) * 2008-07-18 2011-03-21 Oragenics Inc Composiciones para la deteccion y tratamiento de cancer colorrectal.
KR100983386B1 (ko) 2008-09-12 2010-09-20 성균관대학교산학협력단 난소암 진단을 위한 ａｇｒ-2의 신규한 용도
CN101519649B (zh) * 2009-01-22 2010-11-03 上海交通大学 杂交瘤细胞株及其制备方法
WO2012100339A1 (en) * 2011-01-27 2012-08-02 University Health Network Methods and compositions for the detection of pancreatic cancer
US9415088B2 (en) * 2011-02-25 2016-08-16 The Board Of Trustees Of The Leland Stanford Junior University Use of AGR3 for treating cancer
CN102268089A (zh) 2011-07-05 2011-12-07 上海交通大学 Agr2阻断抗体及其用途
CN104203982B (zh) 2011-10-28 2018-08-31 特瓦制药澳大利亚私人有限公司 多肽构建体及其用途

Also Published As

Publication number Publication date
MX2014000260A (es) 2014-09-01
EP2749573B1 (en) 2017-09-13
US9574012B2 (en) 2017-02-21
RU2610665C2 (ru) 2017-02-14
EP2749573A1 (en) 2014-07-02
JP2014520511A (ja) 2014-08-25
TWI588154B (zh) 2017-06-21
AU2012278751B2 (en) 2017-07-20
WO2013004076A1 (zh) 2013-01-10
RU2014103784A (ru) 2015-08-10
TW201319085A (zh) 2013-05-16
EP2749573A4 (en) 2015-03-04
US20170240651A1 (en) 2017-08-24
KR20140093922A (ko) 2014-07-29
SG10201605435TA (en) 2016-08-30
US20140328829A1 (en) 2014-11-06
JP6127043B2 (ja) 2017-05-10
CN103987731B (zh) 2018-04-13
CN103987731A (zh) 2014-08-13
CA2841372A1 (en) 2013-01-10
AU2012278751A8 (en) 2014-03-27
WO2013004076A8 (zh) 2014-02-06
CN102268089A (zh) 2011-12-07
AU2012278751A1 (en) 2014-02-27
BR112014000181A2 (pt) 2017-02-07

Similar Documents

Publication Publication Date Title
AU2012278751A8 (en) AGR2 blocking antibody and use thereof
MX2013009362A (es) Anticuerpo contra el csf-1r.
NZ601588A (en) Methods for treating breast cancer
TN2013000378A1 (en) Anti - sclerostin antibody crystals and formulations thereof
IL228802A0 (en) Bispecific antibodies against 2her and 3cd
IL222359A0 (en) Monoclonal antibodies against her2 antigens, and uses therefor
NZ604007A (en) Monoclonal antibodies against her2 epitope
SG194701A1 (en) Anti-cd40 antibodies and methods of use
PH12016501212B1 (en) Human anti-il-33 neutralizing monoclonal antibody
MX2016008098A (es) Anticuerpos biespecificos del receptor 2 de factor de crecimiento ipidermico himano (her2) y metodo de uso.
CA3019531A1 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
MX342240B (es) Anticuerpos anti-fgfr4 y metodos de uso.
PH12014501427A1 (en) Anti-php-tau antibodies and their uses
HUE037095T2 (hu) Eljárások és reagensek monoklonális ellenanyagok elõállítására
NZ611785A (en) Anti-notch1 antibodies
MX2014002053A (es) Anticuerpos anti -mcsp y metodos de uso.
NZ608033A (en) Anti-ox40 antibodies and methods of using the same
TN2014000107A1 (en) Anti-aplhabetatcr antibody
EP2775305A4 (en) FLUORO-IMMUNOLOGY ASSAY METHOD USING A POLYPEPTIDE COMPLEX CONTAINING A VARIABLE FLUOROMARCATED ANTIBODY REGION
PH12014500841B1 (en) ANTI-HtrA1 ANTIBODIES AND METHODS OF USE
NZ597531A (en) Inhibition of tumor metastasis using bv8- or g-csf-antagonists
EP3242895A4 (en) A novel anti-egfr monoclonal antibody, method of making, and use thereof
EP3722311A4 (en) HUMAN ANTI-IL6 MONOCLONAL ANTIBODIES, METHOD FOR THE PREPARATION AND USE THEREOF
EP2672994A1 (en) Anti-alpha-v integrin antibody for the treatment of prostate cancer
IL238920A0 (en) Human monoclonal antibodies against activated protein c and their uses

Legal Events

Date Code Title Description
FG Grant or registration